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Summary.-The tumour used, designated MT1, is a more radiosensitive form of the
anaplastic MT tumour previously described. No explanation for the increased
radiosensitivity was found, but it was shown not to be due to infection or to a change
in immunological status, growth rate or histology. The sensitivity has remained
constant throughout the present work.
No cytotoxicity in the tumour was observed when 1 mg/g body weight of Ro-07-
0582 was injected immediately after a single dose ofX-rays; indeed a small protective
effect was seen.
A radiosensitization enhancement of 1P5 was achieved with a relatively low drug
dose of Ro-07-0582 in a 5F/4d fractionated regime.
The interval between the injection of a low dose of Ro-07-0582 and the start of
irradiation was found to be critical, the optimum interval being 45-60 min.
The subsequent incidence of distant metastases was not increased by the use of
Ro-07-0582 at the time of "primary" tumour irradiation.
HYPoxic cells have been shown to be
present in animal tumours (Thomlinson,
1960; Kallman, 1972) and are thought to
be responsible for the failure, in some
instances, of X-ray treatment for local
control of human tumours (Fowler, 1972).
One possible method to overcome this
problem of hypoxic cells is the use of
electron-affinic drugs that can mimic the
radiosensitizing effect of 02, but are not
so rapidly metabolized, and hence can
diffuse to and radiosensitize the hypoxic
cells (Adams, 1973).
The most promising compound to date
is the 2-nitroimidazole, Ro-07-0582, which
has been shown to radiosensitize both
bacterial and mammalian cells in vitro
(Asquith et al., 1974) and tumours in situ
(Sheldon and Hill, 1977).
The present work, using local control
of the MT1 tumour, is concerned with
further investigations of this compound:
its cytotoxic effect if given after irradia-
tion; its effect if given with fractionated
X-rays; and the effect of varying the
interval between injection and irradiation.
MATERIALS AND METHODS
The tumour investigated was the ana-
plastic MTI. This is a more radiosensitive
form of the anaplastic MT tumour which we
have previously used in radiosensitization
studies (Sheldon and Hill, 1977). The
change took place in June 1975, and appeared
to have occurred spontaneously, between one
transplant and the next. The radiobiological
response of the tumour has since remained
constant.
The method used has been described in
detail elsewhere (Sheldon and Hill, 1977).
Briefly, fragments of tumour were implanted
s.c. over the sacral region of the backs of
8-week-old female inbred WHT/Ht mice.
On reaching a mean diameter of5 5f0-5 mm,
the tumours were selected for treatment
(which was always given during the morning).
The dose of X-rays required to locally control
500o of the tumours (i.e. the TCD50) was
determined by treating with a range ofEFFECTS OF RO-07-0582 ON LOCAL TUMOUR CONTROL
6-8 X-ray doses, using about 12 mice per dose
group.
Irradiations wAere performed without the
aid of anaesthetics, by placing the mice in
specially constructed lead boxes which had a
portion of the lead cut away to expose the
tumour to a tangential beam of 240 kV
X-rays (15 mA, HVL 1-3 mm Cu, 3-62 gray/
min). To ensure uniform dose throughout
the tumour mass, the mice wNere turned
through 1800 halfway through the irradiation.
The mice were then observed regularly
until they wNere killed at 80 days from the
mid-time of treatment. At the time of
killing, tumours less than 2 mm mean
diameter were scored as "controlled", and
more than 4 mm as "recurrent". Tumours
from 2 to 4 mm would have been considered
ambiguous and rejected from the analysis,
but no tumours fell in this category in the
present Awork. The probability of tumour
control wNas computed using the logit method
of maximum likelihood (Suit, Shalek and
Wette, 1965).
All mice wAere examined post mortem for
the presence of macroscopic metastases.
Hypoxia. This was produced by applying
metal D-shaped clamps across the base of
the tumour to occlude the blood supply. The
clamps, were applied 10 min before com-
mencing irradiation.
Ro-07-0582.- 1-(2-hydroxy-3-methoxy-
propyl)-2-nitromidazole; Misonidazole, was
kindly supplied by Roche Products Ltd. It
was dissolved in warm isotonic saline and
injected i.p. at 0-8 ml per 24-g mouse.
(a) The cytotoxic effect of 1 mg/g body
wNeight of the compound was tested by
injecting it immediately after a single
dose of X-rays.
(b) The effectiveness of the compound
during fractionated treatment was
tested by injecting 0 3 mg/g body
weight 30 min before each of 5 frac-
tions of X-rays given daily in 4 days'
overall time. This interval wNas chosen
before the results for (c) were known.
(c) The importance ofthe interval between
injecting the compound and starting to
irradiate was tested by injecting 0-2
mg/g body weight at various intervals
from 10 to 90 min before starting to
irradiate. This experiment differed
in technique from the others in that
dose response curves were not deter-
mined. Instead, the probability of
tumour control achieved writh a single
dose of 50 gray (5000 rad) was deter-
mined as a function of the interval
used.
RESULTS
Tumour control
In two separate experiments, the
single doses of X-rays required to locally
control 50%0 of the anaplastic MTI
tumours (the TCD5o) were 64 8 (s.e.
range 61 6-68.2) and 63 8 (62.2-65.4)
gray. The control TCD50 used here was
derived by combining both these sets of
data in a single computation of the TCD5o
(i.e. 63-6 gray). Table I shows these
combined data, together with those from
all the other experiments in the present
work. The effect of clamping was to
increase the TCD50 by 5 9 gray.
Assuming a hypoxic Do of 3 6 gray this
would indicate a natural hypoxic pro-
portion of 19° (9-41O s.e. range). A
hypoxic Do of 3 6 gray is compatible with
that observed in the related MT tumour
when assayed in vitro (McNally and
Sheldon, 1977).
Fig. 1 shows the effect of injecting
1 mg/g body weight of Ro-07-0582 im-
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FIG,. I. The probability of local tumouir
control at 80 days after a single (lose of
X-rays, given either alone (X), or with
I mg/g body weight Ro-07-0582 injected
immediately after the irradiation (0).
The dashed line indicates the increased
radioresistance observed when the tumours
were clamped off to render them fully
hypoxic. The horizontal bars show the
TCD50o -s.c. mean.
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TABLE I. Tumnour (Control Data at 80 Days
Single Hypoxic 5-fractioii 5-fraction
X-ray (dose single (lose X-iays oinly 0582+X-rays
(/I I
0/12
5/12
14/ 19
10/11
1 9/ I )
8/8
20/20
0/12
0/12
0/12
7/12
10/12
12/12
4/12
(i/12
7/9
9/1 1
7/7
10(/10I
/)/9
()/I 1
0/12
1/12
9/1 1
9)/9
0582
after X-rays
0/8
0/11
2/12
7/11
11/12
5/5
12/12
1(/10
12/12
6:3-6 69-5 93-7 63-6 68-3
(62-3 64-9) (68 1-70.-9) (92-()-95-5) (63-1 (4-2) (67-169-6)
1 3:
112
5
1 1
72
72
0}
0}
84
70
8
10(6
1 00
4
64
59)
2
6
* To con(leise the table, the mean was taken for X-ray (doses withini 1 gray of each other.
mediately after a single dose of X-rays.
The TCD50 was increased from 63 6 gray
for the control mice which received X-rays
only, to 68-3 gray for those receiving both
X-rays and Ro-07-0582. This corre-
sponds to a protective enhancement ratio
of 0 93 (s.e. range 0 90-0.96). This
observed increase in radioresistance when
Ro-07-0582 was administered after irradi-
ation was similar to that which had been
observed when the tumours were clamped
off to render them fully hypoxic during
the irradiation (dashed line). Thus in this
tumour, Ro-07-0582 appeared to have a
protective rather than a cytoxic effect.
The radiosensitization obtained with
0 3 mg/g Ro-07-0582 in the fractionated
X-ray schedule of 5F/4d is shown in Fig. 2.
The TCD50 for the mice receiving X-rays
only was 93-7 gray, and for those receiving
both Ro-07-0582 and X-rays it was 63 - 6
gray, giving an enhancement ratio of 1 -47
(s.e. rangbe 1*43-1.51).
The importance of the interval between
injecting 0 2 mg/g Ro-07-0582 and start-
ing to irradiate with a single dose of 50
gray of X-rays on the probability of
tumour control is shown in Fig. 3. The
probability (P) of tumour control at 20,
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Foe. 2. The raadiosensitization by 0-3 mg/g
Ro-07 0582 for a 5-fraction-in-4-day radia-
tioIn schedule. The horizontal bars show
TCD50 s.e. mean. ( x ) X-iays alone;
(@) in combinationi with 1Ro---()7-0582.
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Fio:. ,3. The chainge in the probability of
local tuimouir control esuilting from altering
the initeival between the injection of 0 2
mg/g Ro-07 0582 andl the start of X-
irradiation with a single (lose of 50 gray.
'I'he error bar's are 95° confidence limits.
Also showni are the ntumbers of mice perI
poirnt, an(l the level of probability (P)
according to the chi-square(d test, that the
control r'ates afterI intervals of 20, :30, 75
an(i 9() mmis wer-e significantly (different fiom
that at 60 min.
30, 75 and 90 mim differing from that at
60 min is shown according to the chi-
squared test. The control rate was sig-
nificantly lower (P<0.05) for intervals
shorter than 30 mmin and longer than 75
min.
Metastases
Macroscopic metastases were only
observed in the lungs. The incidence of
metastases observed at postmortem exam-
ination is shown in Table I. In both cases
the incidence was lower in the drug-
treated mice than in those that received
X-rays alone. Whereas 500 (7/133) of
the control mice that received a single dose
of X-rays only developed metastases, only
2%o (1/64) of the mice that received
Ro-07-0582 immediately after irradiation
developed metastases. In the fraction-
ated experiment, the incidence of meta-
stases was 8% (7/84) in the mice receiving
X-rays only, and 2% (2/106) in those
receiving both Ro-07-0582 and X-rays.
However, according to the chi-squared
test, this reduction in the incidence of
metastases in the Ro-07-0582-treated
mice is not significant. (P->0 08).
DISCUSSION
Tumour change
The present work is part of a larger
study of hypoxic cell radiosensitization
that we have carried out in vivo, but it is
reported separately here because it was
performed on a more radiosensitive form
of the tumour, which we have designated
MTI to differentiate it from the previously
reported more radioresistant MT (Sheldon
and Hill, 1977). Unfortunately, such a
change in a tumour's radiobiological
response is not uncommon when it is
investigated over a long period of time.
Indeed it is a constant hazard of such
studies, and has been reported previ-
ously (e.g. Peters, 1974; Fowler et al.,
1975).
The change in radiosensitivity of the
present tumour occurred in June 1975,
between one transplant and the next, and
it has since remained at the same level of
radiosensitivity. The change resulted in
a decrease in the dose required to locally
control 50% of the tumours with a single
dose of X-rays from 79-0 (s.e. range
78 2-79.9) to 63-6 (62.3-64.9) gray, with a
corresponding drop in hypoxic proportion
(as determined by rendering the tumour
fully hypoxic by clamping) from 80-1000°
to about 20%.
The reason for the change is uncertain.
Dr H. B. Hewitt kindly tested the tumour
for the presence of infective bacteria, but
was unable to detect any. He was also
unable to detect any histological change.
Similarly, the growth rate of the tumour
remained unaltered (i.e. volume-doubling
time of 1 day from 5-5 to 6 9 mm mean
diameter). We have investigated both
forms of tumour for immunogenicity by
"immunizing" the hosts with heavily
irradiated (HR) cells 19 and 11 days
before determining the number of viable
cells required to produce tumours in 5000
of inoculated sites (TD5o). For the non-
immunized control mice, the TD50 for the
radioresistant MT tumour was 46 cells
and for the radiosensitive MT1 tumour it
was 98 cells. For the mice "immunized"
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by HR cells, the TD50s were 81 and 88
cells respectively. All the TD50 values
fell within 1 s.e. mean, and are therefore
not significantly different from each
other. Thus the change in the tumour
response is unlikely to be due to a change
in immunological status.
The reason for the change in the
tumour remains uncertain. One possible
explanation for the change, that we have
not investigated, is a change in the
tumour's ability to recover from
potentially lethal damage (PLD). Such
recovery has been observed in the original
radioresistant MT tumour, and was
believed to account for the apparent nil
effect on the TCD50 of clamping off of
the tumour to render it fully hypoxic
(McNally and Sheldon, 1977). However,
as mentioned above, there is an observable
effect of clamping on the more radio-
sensitive form of the tumour. Whatever
the mechanism of the change, it did not
result from a gradual drift, but occurred
spontaneously between one transplant
and the next. We consider that it is
most likely to be due to the selection of an
atypical group of tumour cells during one
ofthe transplantation passages by trochar.
We now passage these tumours by
injecting a suspension of cells instead of
small lumps, although for experimental
batches we continue to use the trochar
method of implanting, as this produces
more spherical and discrete tumours.
(.1ytotoxic effects of Ro-07-0582
In vitro Ro-07-0582 has been shown
to be a powerful cytotoxin specifically for
hypoxic cells (Hall and Roizin-Towle,
1975; Moore, Palcic and Skarsgard, 1976;
Stratford and Adams, 1977). In vivo, a
number of workers have investigated how
much of the radiosensitization observed
following a single injection of Ro-07-0582
given before irradiation was, in fact, due
to cytotoxicity. They have done this by
injecting the same quantity of drug after,
instead of before, the irradiation. Their
findings are summarized in Table II. In
all cases, the cytotoxic enhancement ratios
(ER), varying from 0 93 (present work)
to 1 3, are small compared to the observed
total ERs, including radiosensitization, of
1.5-2-3.
However, such in vivo experiments in
mice are likely to underestimate the
clinical potential of Ro-07-0582 as a
specific hypoxic-cell cytotoxic agent. The
in vitro cytotoxicity was only observed
when hypoxic cells were exposed to a
constant drug level for at least several
hours. This cannot be simulated in mice
after a single injection, because of the
drug's short half-life of 1-I5 h (Foster,
personal communication). However, the
TABLE IT.-Review of Radiosensitization by and Cytotoxicity of 1 mg/g Ro-07-0582
ER if drug givein
Experimental Interval Before After
system Tumouir (min) X-rays X-rays Author
Cure WHT Aniap. MT1
Cure C3H Alamm. Ca.
Cure C3H Mamm. Ca.
Cure WHT Sq. Ca. D
Regrowth CBA Ca. NT
Regrowth CBA Sa. F
Regrowth WHT Sq. Ca. D
Regrowth WHT bone Sa. 2
Regrowth WHT fib. Sa.
125IUdR
Cell loss CBA Sa. F
(
20
45
0
0
60-120
0
0
0
2-1*
1*8
2-3
2-0
2-1
1-7
2-2
1*8
1.9
60-120 1.5
0 93
1.0
1*2
1*3
13
1*3
1 *3
1*0
1*1
Present work
Sheldon, Foster & Fowler, 1974
Brown, 1975
Hill & Fowler, 1977
Denekamp & Harris, 1975
Begg, 1977
Hill & Fowler, 1977
Denekamp & Stewart t
Denekamp & Stewart t
1.0 Begg, 1977
* Anaplastic MIT tumour see text.
t Private communication.
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half-life in man is 10-18 h (Foster et al.,
1975), and consequenitly the drug may be
in contact with hypoxic cells in human
tumours for sufficient time for it to be
cytotoxic.
Effect of Ro-07-0582 with frcactionated
X-rays
Ro-07-0582 has been shown to be a
very effective radiosensitizer in vivo with
single doses of X-rays (Sheldon and Hill,
1977). However, it is likely to be less
effective with fractionated X-rays for two
reasons. Firstly, reoxygenation may
reduce the number of radioresistant
hypoxic cells present. Secondly, both
the drug and the X-ray doses per fraction
would have to be less than for single doses.
This loss of effectiveness has been
reported in two murine carcinomas: a
C3H mammary carcinoma, which gave an
ER of 1-8 for a single dose, yielded ERs of
only I 1, 1 2 and 1 2 with the following
fractionated schedules: 3F/4d, 5F/4d and
5F/9d (Sheldon et al., 1976). The CBA
carcinoma NT, which gave an ER of 1P7
for a single dose, yielded ERs of 1 6 and
1 2 for the two fractionation schedules
2F/2d aind 5F/9d (Denekamp and Harris,
1976).
This loss of effectiveness is less
marked in the present tumour. At the
relatively low drug concentration of 0 3
mg/g, anl ER of 1 5 was obtained in the
5F/4d fractionated schedule, which is only
slightly less than the 1 7 observed for a
single dose of X-rays (MT tumour,
Sheldon and Hill, 1977). This small
reductioin might indicate that a little
reoxygenation had occurred, although by
the end ofthe 4-day treatment the tumour
had not begun to shrink, and was about 2
volume doublings larger than when treat-
ment started. Furthermore, we had
observed with the MT tumour (Sheldon
and Hill, 1977) that the ER is less for
X-ray doses below 25 gray than for those
above, and the present fractionated doses
were only 12 7 gray compared with the
single dose of 45 6 gray. Therefore the
small drop in ER may be due to the small
14
X-ray doses per fraction and not to
reoxygenation.
Furthermore, because of the different
half-lives for Ro-07-0582 in mice and men,
the concentration of the drug in human
tumours can equal that in serum, whereas
in mice the tumour level rarely exceeds
400o ofthe serum level (Dische et al., 1977).
Importance of the interval between injection
and irradiation
After administration of Ro-07-0582 its
concentration in either serum or tumour
can be measured either specifically by gas
liquid chromatography or non-specifically
(i.e. as 2-nitroimidazole) by polarography;
such measurements have been made by
Flockhart et al. (1977). However, at
present no technique exists for deter-
mining the concentration of the radio-
sensitizer actually in the hypoxic cells of a
tumour. Therefore, the optimum time
between administering the drug and
starting irradiation can only be determined
radiobiologically in an experiment where
the interval is varied and the tumour
response assayed. With the MT tumour,
we had previously found that, at the
relatively low drug concentration of 0.2
mg/g, an interval of 30 min resulted in a
higher local control rate than an interval
of 90 min (Sheldon and Hill, 1977).
The present results show that the
probability of local tumour control is
significantly lower if the interval is less
than 30 min or more than 75 min, with an
optimum interval around 45-60 min
(Fig. 3). This finding is in accord with
those of some other workers who used
much higher drug concentrations. Brown
(1975) found that the surviving fraction
ofthe EMT6 tumour was lower at intervals
shorter than 30 to 60 min; and Stone and
Withers (1975) that the ER determined
from tumour control of a mammary
carcinoma was greater at 30 min than at
shorter intervals.
Although the interval used is critical
to the success of Ro-07-0582 as a radio-
sensitizer in mice, this is because of its
relatively short serum half-life mentioned
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above. Because of the drug's longer half-
life in man, the interval between adminis-
tering the drug and radiotherapy may not
be so critical (Dische et al., 1977).
To conclude: we have previously
described the development of the present
experimental system, and the radio-
sensitization that was achieved by 5
different compounds when administered
before a single dose of X-rays (Sheldon
and Hill, 1977). The most effective of
these compounds was Ro-07-0582, which
when injected i.p. 30 min before the start
of irradiation, with concentrations from
041 to 1l Omg/g body weight, gave ERs
from 1U5 to 241 respectively. The present
paper reports (albeit on a changed form
of the tumour) further investigations with
this compound. It suggests that the
previously reported ERs were due to
hypoxic-cell radiosensitization and not,
even in part, to hypoxic-cell cytotoxicity.
Furthermore, even with fractionated X-
ray doses, a high level of radio-sensitiza-
tion was observed. Finally, although an
interval between injection of the drug and
the start ofirradiation of 30 min was used
in the above work, this did not produce a
significantly lower probability of local
tumour control than if an optimum
interval of 45-60 min had been used.
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